GPCRVP评分可靠预测GLP1R变异对受体功能的影响
本研究开发了整合分子动力学模拟与AlphaMissense/REVEL的GPCR特异性变异影响预测器GPCRVP,并在58个实验表征的GLP1R变异上训练。验证集显示GPCRVP与实验数据高度一致,假阳性预测较AlphaMissense减少约78%,并对全部已知GLP1R错义变异进行了结构建模,为精准医学提供资源。
要点
- GPCRVP评分整合分子动力学与AI模型,提升GLP1R变异功能预测特异性。
- 验证集中GPCRVP假阳性较AlphaMissense减少约78%。
- GPCRVP可预测全部已知GLP1R错义变异,无需额外实验数据。
核心结论
- GPCRVP是GPCR特异性且可靠的GLP1R错义变异影响预测器,可能有助于临床决策而无需耗时昂贵的实验数据。
研究设计与样本
- 研究开发GPCRVP评分,结合分子动力学模拟与AlphaMissense、REVEL模型,在58个实验表征的GLP1R变异上训练。
主要发现
- GPCRVP与实验数据高度一致,并在独立验证集上表现稳健。
- 验证集中GPCRVP假阳性预测较AlphaMissense减少约78%。
- 为训练和验证集之外的174个已知人类GLP1R错义变异生成结构模型,提供全面预测资源。
关键数值与推荐
- 训练集为58个实验表征的GLP1R变异。
- 验证集假阳性预测较AlphaMissense减少约78%。
- 额外建模174个训练和验证集之外的已知人类GLP1R错义变异。
临床怎么用
- 可用于预测GLP1R错义变异对受体功能的影响,辅助精准医学决策。
- 可能减少对实验验证的依赖,节省时间和成本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The glucagon-like peptide-1 receptor (GLP1R) is a key regulator of glucose homeostasis and body weight, and a major therapeutic target for type 2 diabetes and obesity. Individual disease risk and response to treatments may vary widely depending on the presence of missense variants (MVs) in the GLP1R gene, but accurate prediction of the impact of MVs in the G protein-coupled receptor (GPCR) remains challenging. Here we aimed to generate a reliable and GPCR-tailored predictor of the impact of MVs that is applicable for precision medicine. METHODS: We developed a GPCR variant impact predictor (GPCRVP score) by combining molecular dynamics (MD) simulations with available machine-learning/AI-based models (AlphaMissense and REVEL) to substantially improve the predictive performance of existing models. MD simulations of wild-type and mutant GLP1R complexes were used to extract GPCR-specific structural and dynamic features that capture membrane context, allosteric communication, and mutation-induced contact rearrangements. These descriptors were integrated with existing variant-effect predictors (AlphaMissense and REVEL) and trained on 58 experimentally characterised GLP1R variants to develop GPCRVP, a GPCR-specific variant predictor. RESULTS: The GPCRVP predictor showed strong agreement with experimental data and robust performance on independent validation datasets. Notably, it demonstrated a substantial reduction in false-positive predictions (approximately 78%) in the validation sets compared with AlphaMissense, indicating improved specificity and reliability. Generation of structural models for all known human GLP1R MVs (174 outside the training and validation sets) produced a comprehensive resource showing the predictive impact of all GLP1R MVs. CONCLUSIONS/INTERPRETATION: These findings establish the GPCRVP score as a GPCR-specific and reliable predictor for GLP1R MVs that is likely to be of great relevance for clinical decision-making without the time- and cost-consuming generation of experimental data.
引用
- Lopez-Balastegui M, Lian S, Gao W, et al. The GPCRVP score reliably predicts the impact of GLP1R human variants on receptor function. Diabetologia. 2026. PMID: 42752967. doi:10.1007/s00125-026-06859-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。